Redeye saw a sales development that was not far off our expectations. The total growth compared to the same quarter last year is minimal, but as the second half of 2022 was relatively weak, it is encouraging to see progress. PFAS’s strong uptake is, at this point, covering the other areas that are not growing to the expected potential. With a couple of weak sales quarters, this was a good step in the right direction. We make some minor upward adjustments to our sales estimates, as PFAS looks promising, and the patented products will start to deliver at some point. We increase our Base case to SEK 9.5 per share and our Fair value range to SEK 5 - 17 per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/